Medical Innovations and Future Trends Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Medical Innovations and Future Trends. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Medical Innovations and Future Trends Indian Medical PG Question 1: Vision 2020 India includes all of the following except :
- A. Epidemic conjunctivitis (Correct Answer)
- B. Refractive errors
- C. Cataract
- D. Glaucoma
Medical Innovations and Future Trends Explanation: ***Epidemic conjunctivitis***
- Vision 2020 India primarily focuses on **preventable causes of permanent blindness** and severe visual impairment.
- While contagious, **epidemic conjunctivitis** is typically a self-limiting condition that does not cause permanent blindness, distinguishing it from the core targets of the initiative.
*Refractive errors*
- **Uncorrected refractive errors** are a major cause of visual impairment globally, particularly **myopia**, hyperopia, and astigmatism.
- They are a significant focus of Vision 2020 due to their **high prevalence** and relatively simple correctability with glasses or contact lenses.
*Cataract*
- **Cataract** is the leading cause of blindness worldwide and in India, largely due to aging.
- It is a primary target of Vision 2020, with strategies focusing on **increased surgical access** and output.
*Glaucoma*
- **Glaucoma** is a group of diseases leading to optic nerve damage and irreversible vision loss, often without early symptoms.
- Early detection and management of glaucoma are key components of Vision 2020 to **prevent progressive sight loss**.
Medical Innovations and Future Trends Indian Medical PG Question 2: Which intervention has shown the highest return on investment in national STI control programs?
- A. Mobile testing units
- B. Online partner notification
- C. Integration with HIV services (Correct Answer)
- D. Mass media campaigns
Medical Innovations and Future Trends Explanation: ***Integration with HIV services***
- This approach offers the **highest return on investment** for national STI control programs as it leverages existing infrastructure and funding for HIV services, maximizing resource utilization.
- **Syndromic management of STIs integrated with HIV care** allows for efficient screening, diagnosis, and treatment of both conditions simultaneously, reaching high-risk populations effectively.
- **India's National AIDS Control Programme (NACP)** successfully demonstrates this model, with STI/RTI services integrated into HIV testing and counseling centers, reducing duplication and operational costs.
- **WHO guidelines strongly recommend** this integration strategy as the most cost-effective approach for national STI control programs, particularly in resource-limited settings.
*Mobile testing units*
- While helpful for reaching underserved populations, **mobile units have high operational costs** including staffing, vehicle maintenance, and equipment, which significantly limit their overall return on investment.
- Their effectiveness is often localized and may not provide broad, sustainable impact across an entire national program compared to integrated services.
*Online partner notification*
- This method's reach is limited by **digital literacy and access barriers**, potentially excluding high-risk groups without internet access, particularly relevant in the Indian context.
- While it can improve partner tracing in certain populations, the initial setup costs and limited universal applicability reduce its overall cost-effectiveness compared to integrated clinical services.
*Mass media campaigns*
- These campaigns require **significant financial investment** for broadcast time and creative development, with outcomes that are difficult to quantify in terms of direct STI reduction.
- While effective for raising general awareness, they generate less measurable return on investment for direct STI control services compared to targeted clinical interventions like integrated service delivery.
Medical Innovations and Future Trends Indian Medical PG Question 3: Choose the best method of diagnosis for the clinical sign represented in the image.
- A. Serum copper
- B. Serum ceruloplasmin (Correct Answer)
- C. Karyotyping
- D. PCR
Medical Innovations and Future Trends Explanation: ***Serum ceruloplasmin***
- The image shows a **Kayser-Fleischer ring**, a greenish-brown discoloration in the periphery of the cornea, which is pathognomonic for **Wilson's disease**.
- **Wilson's disease** is a genetic disorder of copper metabolism characterized by **low serum ceruloplasmin** levels (the primary copper-carrying protein in the blood) and increased copper deposition in various tissues.
*Serum copper*
- While Wilson's disease involves copper accumulation, **total serum copper** can be normal or even elevated due to widespread tissue damage releasing copper into the circulation, making it an unreliable diagnostic marker on its own.
- A low serum copper level can be seen, but it is not as specific as low ceruloplasmin, as much of the copper in serum is bound to ceruloplasmin.
*Karyotyping*
- **Karyotyping** is used to analyze the number and structure of chromosomes and is primarily indicated for diagnosing chromosomal abnormalities, such as Down syndrome or Turner syndrome.
- It is not relevant for diagnosing metabolic disorders like Wilson's disease, which is caused by a mutation in a single gene (ATP7B), not a chromosomal aberration.
*PCR*
- **PCR (Polymerase Chain Reaction)** is a technique used to amplify DNA sequences and can be used for genetic testing to identify specific mutations.
- While genetic testing for the **ATP7B gene** mutation is a confirmatory test for Wilson's disease, it is not the primary or best method for initial diagnosis, especially when classic clinical signs and biochemical markers (like low ceruloplasmin) are present.
Medical Innovations and Future Trends Indian Medical PG Question 4: Which among the following drugs is the new FDA approved immune checkpoint inhibitor for endometrial carcinoma?
- A. Ipilimumab
- B. Pembrolizumab (Correct Answer)
- C. Trastuzumab
- D. Nivolumab
Medical Innovations and Future Trends Explanation: **Pembrolizumab**
* **Pembrolizumab** (Keytruda), a **PD-1 inhibitor**, received accelerated FDA approval for patients with **advanced endometrial carcinoma** that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), and has progressed following prior systemic therapy or is not a candidate for curative surgery or radiation.
* This approval was based on data from the KEYNOTE-158 study, demonstrating **durable responses** in these specific subsets of endometrial cancer, highlighting its role in precision oncology.
*Ipilimumab*
* **Ipilimumab** (Yervoy) is a **CTLA-4 inhibitor** primarily approved for the treatment of **melanoma** and renal cell carcinoma, often in combination with nivolumab.
* While it is an immune checkpoint inhibitor, its primary indications and specific FDA approvals do not include **endometrial carcinoma**.
*Trastuzumab*
* **Trastuzumab** (Herceptin) is a **monoclonal antibody** that targets the **HER2 protein**, commonly used in the treatment of **HER2-positive breast cancer** and certain types of gastric cancer.
* It is not an immune checkpoint inhibitor and its mechanism of action is distinct from blocking immune checkpoints like PD-1 or CTLA-4.
*Nivolumab*
* **Nivolumab** (Opdivo) is a **PD-1 inhibitor** with broad FDA approvals for various cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, and others.
* While a potent immune checkpoint inhibitor, **pembrolizumab** received the specific accelerated approval for advanced endometrial carcinoma in the context described, making it the most direct answer for the "new FDA approved" status in this specific indication.
Medical Innovations and Future Trends Indian Medical PG Question 5: Match List I with List II and select the correct answer using the codes given below the lists:
- A. A->2 B->1 C->3 D->4
- B. A->1 B->2 C->4 D->3
- C. A->2 B->1 C->4 D->3 (Correct Answer)
- D. A->1 B->2 C->3 D->4
Medical Innovations and Future Trends Explanation: ***A->2 B->1 C->4 D->3***
**Correct Matching:**
**A. Nosocomial → Hepatitis B viral infection (2)**
- **Nosocomial infections** are hospital-acquired infections contracted in healthcare settings
- **Hepatitis B** can be transmitted nosocomially through contaminated needles, medical equipment, blood products, or during invasive procedures
- This is a classic example of nosocomial transmission
**B. Opportunistic → Cytomegaloviral infection (1)**
- **Opportunistic infections** occur in individuals with compromised immune systems
- **CMV infection** is a prototypical opportunistic pathogen, commonly affecting:
- HIV/AIDS patients with CD4 count <50
- Solid organ transplant recipients
- Bone marrow transplant patients
- Patients on immunosuppressive therapy
**C. Iatrogenic → Influenza (4)**
- **Iatrogenic conditions** are inadvertently caused by medical treatment or procedures
- This pairing is clinically weak as influenza is primarily a community-acquired respiratory infection, not caused by medical intervention
- This represents the official answer key matching for this PYQ
**D. Epornithic → Aplastic anemia (3)**
- **Epornithic** refers to epidemic disease outbreaks in bird populations
- This pairing is clinically incorrect as aplastic anemia is a human bone marrow failure disorder
- This represents the official answer key matching for this PYQ
**Note:** This is a Past Year Question (UPSC-CMS-2016) where the official answer key indicates A->2 B->1 C->4 D->3. While pairings A and B are medically accurate, pairings C and D have clinical inconsistencies that students should be aware of.
*Incorrect A->2 B->1 C->3 D->4*
- While correctly matching Nosocomial→Hepatitis B and Opportunistic→CMV
- Incorrectly pairs Iatrogenic→Aplastic anemia and Epornithic→Influenza
- Does not match the official answer key
*Incorrect A->1 B->2 C->4 D->3*
- Incorrectly pairs Nosocomial→CMV (though CMV can be nosocomial, Hepatitis B is the better match here)
- Incorrectly pairs Opportunistic→Hepatitis B (not typically classified as opportunistic)
- Does not match the official answer key
*Incorrect A->1 B->2 C->3 D->4*
- All pairings are incorrect
- Does not match the official answer key
More Medical Innovations and Future Trends Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
